Lars Engstrand

Lars Engstrand

Professor/Senior Physician
Telephone: +46852482528
Visiting address: Bioclinicum, 17164 Stockholm
Postal address: C1 Mikrobiologi, tumör- och cellbiologi, C1 CTMR Engstrand, 171 77 Stockholm
Part of:

Articles

All other publications

Grants

  • Swedish Research Council
    1 January 2024 - 31 December 2026
    Our gut microbiome is affected by many factors, including drug use. The first years of life are crucial to establish a healthy, stable gut microbiome, yet infancy is also when most antibiotics are used and many receive gastric acid inhibition. As these drugs are known to disrupt the adult microbiome, the effects in infants could be worse. We will assess how these drugs affect the microbiome and health during early life. First  we will assess the gut microbiome of 3000 babies, born into our large Swedish longitudinal pregnancy microbiome cohort. Second, 400 infants operated during their first days/months of life will be enrolled, of which part receive routine gastric acid inhibition for at least one year. Through repeated stool microbiome collection, questionnaires and registry linkages, we can assess how their microbiome and health are affected and restored. The third and fourth projects are based on the high quality nationwide Swedish registries, to assess how maternal/early life drug use affects the risk of neonatal complications and infections.  In the fifth project, we will assess global antibiotics and gastric acid inhibitors utilisation during infancy (meta-analysis).  With these projects, we want to contribute to the understanding of drug-microbiome interactions in young children, and understand the long-term health consequences. These projects can have direct clinical implications, by contributing to better prescription practices and reducing inappropriate intake.
  • Swedish Research Council
    1 January 2021 - 31 December 2023
  • Pandemic preparedness - high-throughput analysis and surveillance
    KAW
    1 June 2020 - 31 December 2025
    KI transformed its activities in many ways as a response to the pandemic. In just four weeks, the Centre for Translational Microbiome Research converted from a research lab to a diagnostic lab to assist with PCR tests on the national level. In 2020 alone this lab analysed over half a million diagnostic COVID-19 tests and during the pandemic > 135 000 WGS of SARS Cov-2 have been delivered to Public health Agency (approx 70% of all sequenced strains in Sweden during the pandemic). A collaborative network and the flexible cooperation with the health care sector and hospitals in Sweden is the goal for the National Pandemic Center at Karolinska Institutet.
  • Oncobiome
    EU collaborative network
    1 May 2018 - 30 June 2025
  • Centre for Translational Microbiome Research, CTMR
    Ferring Pharmaceutical
    1 January 2016 - 31 December 2023
  • Financing of Swedish sub-project within the project VOLGA CORE. Call 2013 in the ERA-Net EuroNanoMed II.
    Swedish Research Council
    1 January 2014 - 31 December 2016
  • Deutsche Forschungsgemeinschaft
    1 January 2006 - 31 December 2015

Employments

  • Professor/Senior Physician, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 2020-
  • Visiting Professor, Microbiome related mresearch, Dept Medicine, New York University School of Medicine, 2012-2012
  • Visiting professor, Microbiome related research, Dept Microbiology, School of Biotechnology & Biomolecular Sciences, Univ New South Wales, Sydney, Australia, 2004-2005

Degrees and Education

  • Docent, Uppsala Universitet, medicinska fakulteten, 1993
  • Associate Professor, Clinical Microbiology, Dept Bacteriology, Uppsala University, 1993
  • Medical Doctor, specialist, Clinical bacteriology, Uppsala University Hospital, 1992
  • PhD, PhD, Helicobacter pylori - New diagnostic tools, clinical and experimental studies on local and systemic immune response, Faculty of Medicine, Dept Clinical Bacteriology, Uppsala University, 1992

Leadership and responsibility assignments

  • Research team leader, National Pandemic Center, NPC, Microbiology, Tumor and Cell biology, MTC, Karolinska Institutet, 2020-2026
  • Research team leader, Centre for Translational Microbiome Research, CTMR, Microbiology, Tumor and Cell biology, MTC, Karolinska Institutet, 2016-2026
  • Research team leader, Engstrand group, Microbiology, Tumor and Cell biology, MTC, Karolinska Institutet, 2002-2026

Committee work

  • Chair, Swedish Society for Clinical Microbiology, 2009-2012
  • Member, European Helicobacter and Microbiota Study Group, EHMSG, 2001-2025
  • Member, Zoonoses board, 1997-2007

Visiting research fellowships

  • Research assistant, Baylor College of Medicine, Performed one year as a research assistant in collaboration with Dr David Graham - 3 papers included in the thesis after return to Sweden, 1990-1991

News from KI

Events from KI